CDK4 and breast carcinoma: For instance, CDK4/6 inhibitors are providing survival benefit to the certain types of breast cancer characterized by G0/G1 acceleration induced by the CDK4/6-RB1 pathway (Goel and Tolaney, 2019; Zhang et al., 2019).